Neurofibromatosis Therapeutic Acceleration Program

Accelerating the development of effective therapeutics for plexiform and cutaneous neurofibromas

[JHTV @JHTechVentures]

In case you missed it, our December newsletter is packed with highlights from 2025.

- Check out exciting innovations
- Learn about upcoming events and resources
- Discover how we’re driving impact through entrepreneurship and tech commercialization

https://t.co/3l88Qkf8DG

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

A powerful opportunity to advance innovative therapies and repurpose treatments — accelerating discoveries that can translate into real impact for patients. #EndNF #NFResearch #RareDisease #Innovation

[Children's Tumor Fdn @ChildrensTumor]

🚨 Application for the 2025 Drug Discovery Initiative is OPEN! NF researchers, this is your chance to advance innovative therapies and repurposed treatments or validate new NF targets. Deadline: February 2, 2026 by 4 PM EST

🔗 Apply now: https://t.co/H4OloIadbY

#EndNF

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

NTAP is proud to support @VasuLabUCSF and team's research published in @JCI_insight "Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma" #EndNF #NFResearch

[JCI insight @JCI_insight]

NF1 is frequently mutated in #glioblastoma, yet therapies targeting this alteration often fall short.

@VasuLabUCSF & team @UCSF now show NF1 mutant glioblastomas exhibit prognostic signatures with distinct sensitivity to MEK inhibition: https://t.co/FRfozC2Arh

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

A powerful tribute to Dr. Verena Staedtke’s vision. Huge congratulations to Dr. Bai, @jblakel3, and the NTAP/JH/KKI teams for this exciting step forward. Grateful for the progress — and hopeful for what’s ahead. #EndNF #NFResearch

[JHTV @JHTechVentures]

Honoring Verena Staedtke’s vision, @JohnsHopkins researchers, led by Renyuan Bai w/ support from Jaishri Blakeley at @ntapresearch, are advancing gene therapy for NF1. An AAV vector delivering neurofibromin shows promise + hope for patients. https://t.co/X1MEWqhjwF

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

A major milestone for the NF1 community. Congratulations to all involved. Here's to continued momentum in NF research and drug development! #EndNF #NFResearch

[FDA Oncology @FDAOncology]

#FDA approves a treatment for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. https://t.co/KGjyhJr3n0

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

NF1 Researcher? NTAP launched a Scholars program to support early-career PhD-level scientists.
LOIs are due on October 20th. Apply today!

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

1 day way!
Join us tomorrow at 10AM for the Francis Collins Scholars Information session.

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

Are you an early-career clinician-scientist? Ready to make an impact on NF1 research? Join us for an information session on the Francis Collins Scholars Program.
Wednesday, October 1, 2025 @ 10 AM EST
🔗 Register here: https://t.co/4fxFBjIFTD
#Research #EndNF #NF1

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

Are you an early-career clinician-scientist? Ready to make an impact on NF1 research? Join us for an information session on the Francis Collins Scholars Program.
Wednesday, October 1, 2025 @ 10 AM EST
🔗 Register here: https://t.co/4fxFBjIFTD
#Research #EndNF #NF1

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

Great to host @vlmerker yesterday! She highlighted how many with NF1 lack access to specialty clinics-and how decentralized trials + virtual interventions can help bridge the gap. Exciting work on NF1-health surveillance & proposed mobile apps for pain management.#EndNF #research

[Children's Tumor Fdn @ChildrensTumor]

Fueling the next wave of NF research: Nearly $1.5M in Young Investigator Awards will drive cutting-edge science, smarter care & real solutions for NF1, NF2-SWN & SWN. Meet the early-career scientists shaping NF’s future: https://t.co/BSAlaSPfS5

[Children's Tumor Fdn @ChildrensTumor]

App open thru 9/8! Junior faculty, fellows, postdocs & PhD students in #NFresearch—apply now for the NFYIF: a career-catalyzing event for mentorship, productivity & community

https://t.co/9Zr406jCn6

#EndNF #Neurofibromatosis #YoungInvestigators #PostdocLife #PhDlife #ceconcepts

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

Incredible time for the Francis Collins Scholars community! Our 7 summer interns shared powerful NF1 research on MPNST, optic gliomas, GI symptoms & neuropsychiatric profiles. Huge thanks to mentors & supporters! #FrancisCollinsScholars #NFResearch

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

🚨Updated Criteria!
NTAP @HopkinsMedicine is funding early-career PhD (or equivalent) scientists focused on NF1 🧬
Learn more: NF1 Laboratory Scholars Program—mentorship, salary + project support! 🔗https://t.co/bcctPpiwJ7
· LOI due: Oct 20, 2025
#EndNF

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

🚨 Just 20 days left! 🚨
Apply by Aug 13 for up to $50K from the DHART SPORE DRP & CEP Awards to support NF1 & Rasopathy research. Open to clinical, population & basic science investigators.
🔗 https://t.co/3X8nGUG1S0
#NF1 #ResearchFunding #DHARTSPORE

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

🚨 Double the funding, double the chance! Apply now for the DHART SPORE Developmental Research Program (DRP) & Career Enhancement Program (CEP) Awards. Don’t miss out!
🔗 Apply here: https://t.co/hWxt8PzZzh
🗓️ Deadline: August 13, 2025

[IU Simon Comprehensive Cancer Center @IUCancerCenter]

The cancer center’s D. Wade Clapp, MD, and colleagues have published their latest findings in the Journal of Neuro-Oncology. Learn more: https://t.co/SLa386gtkO. #ResearchCuresCancer #NCIcomprehensive @JNeurooncol

[Penn Neurosurgery @PennNSG]

We're excited to have @BettegowdaMDPHD from @HopkinsNsurg join us this week for our #Neurosurgery Grand Rounds!

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

Congrats! Excited to see the next generation of scientists driving discovery for the NF1 community. Make this summer count! 🔬🧬

#NF1 #Research #FutureScientists #SummerInterns #TeamScience

[BRIDGE Lab - Stanford University @BridgelabU]

Please join us in welcoming our amazing summer interns to BRIDGE Lab!

We’re thrilled to have Tali, Catalina, and Annetta join the team. Each of them brings curiosity, enthusiasm, and fresh perspective to our work, and we’re excited to learn and grow together this summer.

[Neurofibromatosis Therapeutic Acceleration Program @ntapresearch]

Pipeline of experts advances discovery in neurofibromatosis https://t.co/VVEGLrcvM0 via @HubJHU Accepting applications now for the 2026 Francis Collins Scholars Program. #EndNF #NFResearch

[Sage Bionetworks @Sagebio]

🧬 Help Advance Genomic Interpretation—Join a CAGI7 Challenge!

Sage Bionetworks is excited to support the recently launched CAGI7 (Critical Assessment of Genome Interpretation) challenges—open to researchers, data scientists, and students who want to help predict the functional impact of genetic variants.

8 challenges are already open for submission. These include:

🔹 BARD1: Predict how single nucleotide variants affect RNA abundance and cell survival—using data from saturation genome editing of a key tumor suppressor gene.

🔹 ARSA: Predict the stability of 8,867 missense variants in Arylsulfatase A, linked to the lysosomal storage disorders.

🔹 ATP7B: Model the functional effects of ATP7B missense variants—key to understanding Wilson disease, a disorder of copper metabolism that affects the liver and brain.

Work with cutting-edge data, get credit, and contribute to a global open science effort to improve genetic prediction models.

➡️ Explore the open challenges and register today
https://t.co/fsXes2sdoo

#CAGI7 #openscience #datachallenges